Dina Schneider: Excited about our recent publication on Armored TGFBRIIdn ROR1-targeting CAR T cells for solid tumors
Dina Schneider, Director of Immuno Oncology and Cell Therapy at
“Excited about our recent publication on Armored TGFBRIIdn ROR1-targeting CAR T cells for solid tumors. We discovered that tumor- activated ROR-1 targeting CAR T cells themselves are in part responsible for production of TGF beta in the tumor microenvironment, and the armor protects them from TGF beta-mediated immunosuppression.
Grateful to our entire team for bringing this project to fruition, and hopeful that it will lead to better clinical outcomes in solid tumors.”
Source: Dina Schneider/LinkedIn
About OncoDaily
OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time it became one of the leading oncology media platforms globally.
OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.
The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we”.